Harnessing the placebo effect: A practical review of mechanisms and clinical applications

  • Cleveland Clinic Journal of Medicine
  • November 2026,
  • 93
  • (11)
  • 669-676;
  • DOI: https://doi.org/10.3949/ccjm.93a.25057

ABSTRACT

The placebo effect is a powerful psychobiological phenomenon that significantly influences clinical outcomes in a wide range of medical conditions. Conversely, the nocebo effect, whereby negative expectations worsen symptoms or generate adverse effects, can undermine treatment efficacy, increase symptom burden, and reduce medication adherence. This review examines the historical evolution, neurobiological underpinnings, and key determinants of the placebo and nocebo responses. Practical strategies are outlined to ethically harness placebo effects and minimize nocebo responses in clinical practice.

KEY POINTS
  • Placebo effects are driven by expectation, conditioning, and the therapeutic context, and can significantly improve outcomes in common medical and psychiatric conditions.

  • Nocebo effects, triggered by negative expectations or communication, can lead to worsening symptoms and reduced treatment adherence.

  • Factors influencing placebo and nocebo responses include treatment attributes, patient characteristics, and clinician factors.

  • Practical applications involve maximizing placebo effects through positive clinician-patient interactions and personalized interventions while minimizing nocebo responses through effective communication, thereby improving quality of life, treatment adherence, and overall clinical outcomes.

The placebo effect is one of the most intriguing phenomena in medicine, demonstrating the profound influence of psychological and contextual factors on clinical outcomes. While traditionally viewed as a nuisance variable in clinical trials, placebo responses have been found to involve complex neurobiological mechanisms and can produce clinically meaningful improvements across diverse conditions. This well-documented phenomenon occurs when patients receive inactive treatments and experience clinical improvement through psychological and neurobiological processes, including expectation and conditioning. Conversely, the nocebo effect occurs when negative expectations produce adverse outcomes, triggering genuine physical symptoms, increased reporting of side effects, and reduced medication adherence.1–4

See related editorial, page 677

By understanding these mechanisms, we can harness placebo responses while minimizing nocebo effects to enhance treatment outcomes. This review examines the neurobiological mechanisms underlying placebo and nocebo effects, identifies patient and clinician characteristics that affect responses, and provides strategies for ethically maximizing placebo benefits while minimizing nocebo harms in clinical practice.

HISTORICAL PERSPECTIVE

The word placebo is Latin for “I shall please.” It first appeared in the medical literature in the mid-1700s, when the famous Scottish physician and teacher William Cullen used it to describe his occasional practice of prescribing a drug to please the patient but without expecting it to do any good.5,6 Thus, the meaning of the term has shifted: we now consider a placebo to be an inactive substance, given in hopes of producing some psychological or physiologic benefit, or as a comparator in a clinical trial of a new drug.

The scientific exploration of placebos evolved dramatically in the mid-20th century through the work of Dr. Henry K. Beecher, an American anesthesiologist. It is said that while serving during World War II in a field hospital in Italy, Dr. Beecher faced a critical situation when a wounded soldier needed surgery but no morphine was available. Out of desperation, he injected the soldier with saline. To Dr. Beecher’s astonishment, the soldier relaxed, allowing the operation to proceed without anesthesia.7 This profound moment revealed the powerful influence of the mind over the body, leading him to dedicate his career to studying the placebo response.5 His landmark 1955 paper, “The Powerful Placebo,” established placebos as a legitimate field of scientific inquiry.8

As this research gained prominence, grave ethical violations such as the Tuskegee Syphilis Study exposed the urgent need for oversight.9 In this study, conducted between 1932 and 1970 to observe the natural history of untreated syphilis, Black men were denied available effective treatment without their informed consent. In response, the Declaration of Helsinki in 1964 formalized rigorous standards for placebo research while elevating patient protection as a fundamental principle.10

HOW DO PLACEBOS WORK?

Placebo and nocebo effects are psychobiological phenomena driven by expectation and conditioning that activate specific neurotransmitter systems and brain networks. While placebo effects enhance treatment outcomes through positive expectations, nocebo effects undermine them through negative expectations.1

Expectation involves conscious anticipation of benefit or harm based on previous beliefs, contextual cues, or clinician suggestions. Conditioning operates through learned associations between treatment cues (such as pill appearance or clinical setting) and therapeutic outcomes from previous experiences. These mechanisms often work synergistically, with conditioning strengthening expectations and expectations modulating conditioned responses, as demonstrated in both human and animal studies.11

Neural pathways and neurotransmitter systems

Placebo responses activate distinct neural pathways depending on the condition.1,12 In Parkinson disease, placebo treatment activates the dopaminergic reward system, particularly the nucleus accumbens, brainstem, and prefrontal cortex, which triggers dopamine release in the striatum and alters basal ganglia firing patterns.13 In depression, it induces metabolic changes in the prefrontal cortex, subgenual cingulate, parahippocampus, and thalamus.13 For pain, it activates the amygdala, anterior cingulate cortex, and prefrontal cortex, triggering descending inhibitory pathways to the spinal cord.1

Key neurotransmitter systems. Placebo effects involve release of endogenous opioids, endocannabinoids, dopamine, oxytocin, and vasopressin, with specific roles depending on the condition.1 Endogenous opioids are central to placebo analgesia, activating pain-processing regions including the rostral anterior cingulate cortex, prefrontal cortex, insula, nucleus accumbens, and periaqueductal gray.1,14 The mu-opioid system also modulates placebo effects in depression through emotion regulation and stress responses.14 Dopamine plays a critical role in placebo effects in Parkinson disease but not in chronic or acute pain conditions.1

For nocebo effects, cholecystokinin mediates hyperalgesia through anticipatory anxiety. Cholecystokinin antagonists, such as proglumide, block nocebo-induced hyperalgesia, while diazepam reduces both hyperalgesia and associated hyperactivity of the hypothalamic-pituitary-adrenal axis.1,15

Beyond pain: Immune and dermatologic models

Recent studies extend placebo research to the immune and dermatologic systems. Take itching, for example. Meeuwis et al16 conducted a systematic review of 31 studies in animals (mostly rodents) and 55 studies in humans and found that placebo and nocebo effects can be induced by various methods, including conditioning, although there were heterogeneous findings across studies. Conditioning with histamine administration in rodents led to changes in histamine levels and scratching behavior when the cue was presented alone, demonstrating neurobiological modulation of peripheral immune responses.

In immune models, Pacheco-López et al17 reported that behavioral conditioning with immunomodulatory drugs produces learned immunosuppression, with conditioned cues suppressing lymphocyte proliferation and cytokine production. The insular cortex and amygdala are central to conditioned immune modulation, with noradrenaline acting as a key neurotransmitter.

Genetic influences

Genetic variants modulate placebo and nocebo responsiveness through polymorphisms in dopamine, opioid, and endocannabinoid genes.1,18 Interactions between these genetic variants can predict placebo analgesic responses, with individuals carrying specific combinations showing significant placebo effects.18 However, these genetic factors likely represent only a portion of the heritable factors influencing placebo and nocebo responses, and genetic variants alone cannot fully predict placebo responsiveness.19

Open-label placebos

Deception is not required for placebo effects. Open-label placebos are inert substances, administered with full disclosure to patients, that nevertheless produce clinically meaningful improvements in multiple conditions.20 A meta-analysis in 2021 of 11 randomized controlled trials found a significant overall effect for open-label placebos compared with no treatment in back pain, cancer-related fatigue, attention-deficit hyperactivity disorder, allergic rhinitis, major depression, irritable bowel syndrome, and menopausal hot flashes.21 An updated meta-analysis in 2025 confirmed these findings with a small positive effect, with larger effects shown in clinical samples than in nonclinical samples and in self-reported vs objective outcomes.11

Open-label placebos may differ in their mechanisms from traditional placebos. While the precise mechanisms remain under investigation, some evidence suggests that conscious expectation may play a less prominent role than in traditional placebo responses, with alternative mechanisms such as unconscious processes potentially contributing to the effect.22

FACTORS INFLUENCING PLACEBO AND NOCEBO RESPONSES

Beecher and other researchers in the 1940s and 1950s estimated that 30% to 40% of patients improved from placebo interventions.23 Moreover, the placebo response shows remarkable durability, with a study that tracked over 3,000 patients in clinical trials of antidepressants finding that 79% of placebo responders maintained their gains for more than 12 weeks.24 However, in a meta-analysis in 2001, Hróbjartsson and Gøtzsche23 said “we found little evidence that placebos in general have powerful clinical effects.”

In practice, the magnitude and direction of placebo and nocebo effects are shaped by several factors. Understanding these determinants enables targeted strategies to optimize therapeutic outcomes.1,25,26 Table 118,27–33 summarizes the key factors influencing placebo and nocebo responses.

View this table:
TABLE 1

Factors influencing placebo and nocebo responses

Treatment characteristics

Physical attributes of treatments significantly affect patient expectations and outcomes.1 For example, pill color influences perceived effects, with red, yellow, and orange being associated with stimulant effects, while blue and green are perceived as having tranquilizing effects.27 Route of administration also matters: more-invasive treatments such as injections generally produce stronger placebo responses than oral medications.28 Finally, perceived cost affects outcomes. In a study in patients with Parkinson disease, an “expensive” placebo produced significantly better motor improvement than a “discount” placebo.29

Patient characteristics

Individual patient factors play an important role on the placebo and nocebo response.1

Personality. Optimism and suggestibility do not appear to be as closely associated with placebo responsiveness as previously believed.34,35 However, nocebo effects are more likely in those who are more anxious, have a history of medically unexplained symptoms, or have greater psychological distress.1 Patients with an internal locus of control (ie, believing they can influence outcomes) may experience stronger placebo effects.30

Medical history and previous treatment experiences significantly influence placebo responses through learning and classical conditioning mechanisms.1 For example, in one report, 30% of women undergoing chemotherapy for breast cancer had anticipatory nausea when exposed to previously neutral environmental cues associated with the infusion (eg, traveling to the hospital, entering a room that resembles an infusion room).36

Genetics. Placebo responsiveness is influenced by the “placebome,” a collection of genetic variants and single-nucleotide polymorphisms.18

Clinician factors

The quality of the clinician-patient relationship significantly influences placebo and nocebo responses.1,31 Patients who perceive their clinicians as empathetic, caring, warm, nonjudgmental, and competent experience better outcomes, including reduced severity and duration of symptoms.32 Patients who perceive their clinicians as empathetic report not only subjective improvement but also objective reductions in inflammatory markers such as interleukin 8 and neutrophil counts.37 In an irritable bowel syndrome trial, an “augmented” relationship characterized by warmth, attention, and confidence produced the largest improvements in symptom scores, adequate relief, and quality of life.38

Evidence from a meta-analysis confirms that empathic clinical interactions improve pain, anxiety, and satisfaction with no adverse effects.39

Therapeutic touch represents a powerful embodiment of empathy that strengthens the therapeutic alliance and augments placebo responses. Touch serves as a form of embodied empathic communication, allowing clinicians to share emotions, demonstrate presence, and establish human connection in ways that verbal communication alone cannot achieve.40

Negative communication patterns trigger nocebo effects.1,33 Lack of eye contact, monotone speech, absence of empathetic remarks, and minimal facial expression decrease pain tolerance and diminish placebo responses.

PRACTICAL APPLICATIONS IN CLINICAL SETTINGS

The following strategies require no additional appointments or resources and represent modifications to existing clinical interactions that leverage context, relationship, and communication for therapeutic benefit.1 Table 2 provides a summary of practical applications for clinical practice.

View this table:
TABLE 2

Practical applications for optimizing placebo effects and minimizing nocebo effects

Enhance effective communication using evidence-based strategies

Clinicians can implement structured communication approaches that strengthen the therapeutic relationship and optimize patient outcomes. Evidence-based communication models such as Cleveland Clinic’s Relationship, Establishment, Development, and Engagement (REDE) framework can help clinicians establish initial rapport, develop deeper understanding and active listening, and maintain sustained engagement through supportive presence and body language.41 Such frameworks transform communication from an intuitive skill into a deliberate practice and have been shown to improve patient experience scores and clinician wellness.41,42

Empathetic clinician interactions produce measurable clinical benefits. Positive nonverbal behaviors (smiling, using a strong tone of voice, making eye contact, leaning toward the patient, using body gestures) contribute to lower reported pain and higher placebo effects. Negative behaviors (no smile, monotone voice, no eye contact, leaning backward, no gestures) contribute to higher reported pain levels, lower pain tolerance, and nocebo effects.

Enhance expectations through positive verbal suggestions

Positive verbal framing substantially increases treatment efficacy.32 Describing a medication as “a powerful pain reliever” produces greater benefit than silent administration. Heightened expectations of treatment benefit increase response to analgesics (morphine, remifentanil, topical lidocaine), psychiatric medications (diazepam), procedural interventions (deep brain stimulation, surgical interventions), and complementary approaches (acupuncture).

Baseline expectations predict treatment outcomes in psychiatric conditions.32 In posttraumatic stress disorder, enhanced baseline expectations were associated with higher probability of early response to sertraline and better outcomes at 10 weeks.43 In difficult-to-treat depression, higher positive treatment expectations at baseline were associated with greater odds of remission with repetitive transcranial magnetic stimulation.44

Clinicians should quantify and assess patients’ expectations systematically.32 Ask patients to rate their expectations about treatment benefit on a scale from 0 (no benefit) to 100 (maximum imaginable benefit). In a randomized trial, helping patients understand their expectations of elective cardiac surgery reduced disability outcomes 6 months after surgery.45 In another study, educating patients about coping strategies before intraabdominal surgery led to a 50% reduction in post-operative pain and narcotic use.32,46

Minimize nocebo response through strategic communication

To minimize the nocebo response, frame information positively while still being honest. For example, present the proportion of patients who do not experience side effects rather than the proportion who do. When discussing treatment outcomes, you can say “80% of patients experience relief ” rather than “20% don’t respond.” Closely couple information about side effects with information about benefits and describe side effects in a supportive yet non-deceptive way. Further strategies include the following:

Balance informed consent with reassuring language. All potentially dangerous and medically significant side effects must still be clearly and accurately described. Consider “contextualized informed consent,” where patients are educated about the nocebo effect and then asked whether they wish to be informed about benign, nonspecific side effects that are not of medical concern. Expert consensus supports that communicating general information about placebo and nocebo effects to patients could be beneficial,47 though such information needs to be adjusted to match the specific clinical context.

Explore mistaken beliefs and previous negative experiences. Ask patients about previous bothersome side effects, what worried them about those effects, and what they presume is the significance of current side effects. Reassurance that a side effect may be bothersome but is not harmful or medically dangerous may relieve the anxiety contributing to it.

Consider ethical applications

Explore open-label placebos as potential adjunctive treatments.11 Some research supports the efficacy of an open-label placebo approach, in which the treatment effect of an active drug is enhanced by concurrently administering a placebo and informing the patient (truthfully) that the addition of a placebo has been shown to enhance the beneficial effects of active drugs.

As noted, meta-analyses of randomized controlled trials found that open-label placebos had significant effects in multiple conditions (back pain, cancer-related fatigue, attention-deficit hyperactivity disorder, allergic rhinitis, depression, irritable bowel syndrome, menopausal hot flashes), with larger effects observed in clinical vs nonclinical samples.11 In irritable bowel syndrome, open-label placebo treatment produced clinically meaningful improvements, suggesting blinding may not be necessary for placebos to be effective.38

Maintain transparency and avoid exaggeration while emphasizing the potential benefits of treatment. Present patients with realistic possible effects of the intervention to avoid a discrepancy between what is expected and what actually occurs. Clinicians should aim to describe treatments in a realistic yet positive way that highlights potential placebo effects in a non-paternalistic manner.

Use educational strategies and conditioning. Consider using educational strategies such as video clips of patients recounting positive treatment experiences to improve outcomes through social learning mechanisms. Favor positive associations and minimize negative associations between the therapeutic intervention and contextual factors. Consider administering interventions in a positive context, suggesting coping strategies, and providing multisensory cues (eg, sight, smell, and taste stimulations associated with the active medication) to promote conditioning.

Personalize the response

Consider individual factors when tailoring interventions. Personality traits, medical history, and experiences with treatment all influence placebo and nocebo responsiveness. Among persons taking active drugs, the nocebo effect is more likely to occur in those who are more anxious, have a history of medically unexplained symptoms, or have greater psychological distress.

Explore patients’ previous treatment experiences to address concerns and build on previous positive responses.

Collect information about patients’ expectations concerning treatment and outcomes as part of the medical history, and encourage discussion to align patients’ expectations with anticipated therapeutic outcomes.

HOW WE DELIVER CARE MATTERS AS MUCH AS WHAT WE DELIVER

The placebo effect constitutes a neurobiologically mediated therapeutic mechanism arising from the complex interplay of expectation, classical conditioning, and contextual factors within the clinical encounter. As demonstrated across multiple medical and psychiatric conditions, placebo effects engage distinct neural pathways, including dopaminergic, opioidergic, and endocannabinoid systems, that produce measurable changes in physiology and symptoms. Conversely, nocebo responses, mediated by other pathways, can significantly attenuate treatment efficacy and compromise patient adherence.

Therapeutic outcomes are determined not solely by the pharmacologic or procedural properties of an intervention but also by treatment characteristics, patient-specific factors, and clinician behaviors that modulate placebo and nocebo responses. Recognizing that every patient encounter has the potential to harness the placebo effect underscores a fundamental truth: how we deliver care matters as much as what we deliver. By fostering strong clinician-patient relationships and training healthcare professionals in effective communication strategies, we can enhance placebo responses while minimizing nocebo effects.

Future research should focus on developing evidence-based protocols for ethically maximizing placebo mechanisms and minimizing nocebo responses across diverse clinical populations and treatments. Also, identifying neurobiological and psychological predictors of placebo responsiveness may enable personalized medicine approaches that match patients to optimal therapeutic contexts. Ultimately, integrating placebo science into clinical practice represents an opportunity to enhance treatment outcomes, improve quality of life, and optimize healthcare delivery without additional pharmacologic burden.

DISCLOSURES

Dr. Viguera has disclosed consulting for UpToDate. Dr. El Zein reports no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

REFERENCES

  1. 1
    ↵
    CollocaL, BarskyAJ. Placebo and nocebo effects. N Engl J Med 2020; 382(6):554–561. doi:10.1056/NEJMra1907805
  2. 2
    RaghuramanN, CollocaL. Clinical neuroscience and neurobiology of placebo and nocebo effects. Int Rev Neurobiol 2025; 184: 179–197. doi:10.1016/bs.irn.2025.09.001
  3. 3
    BarskyAJ, SaintfortR, RogersMP, BorusJF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002; 287(5): 622–627. doi:10.1001/jama.287.5.622
  4. 4
    ↵
    Bagnis A, Meeuwis SH, Haas JW, et al. A scoping review of placebo and nocebo responses and effects: insights for clinical trials and practice. Health Psychol Rev 2025; 19(2):409–447. doi:10.1080/17437199.2025.2471792
  5. 5
    ↵
    CzerniakE, DavidsonM. Placebo, a historical perspective. Eur Neuropsychopharmacol 2012; 22(11):770–774. doi:10.1016/j.euroneuro.2012.04.003
  6. 6
    ↵
    KerrCE, MilneI, Kaptchuk TJ. William Cullen and a missing mind-body link in the early history of placebos. J R Soc Med 2008; 101(2):89–92. doi:10.1258/jrsm.2007.071005
  7. 7
    ↵
    BenedettiF. Historical evolution of the scientific investigation of the placebo analgesic effect. Front Pain Res (Lausanne) 2022; 3:961304. Published August 10, 2022. doi:10.3389/fpain.2022.961304
  8. 8
    ↵
    BeecherHK. The powerful placebo. J Am Med Assoc 1955; 159(17):1602–1606. doi:10.1001/jama.1955.02960340022006
  9. 9
    ↵
    AngellM. The ethics of clinical research in the Third World. N Engl J Med 1997; 337(12):847–849. doi:10.1056/NEJM199709183371209
  10. 10
    ↵
    Declaration of Helsinki. Recommendations guiding doctors in clinical research. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964. www.wma.net/wp-content/uploads/2018/07/DoH-Jun1964.pdf. Accessed October 16, 2026.
  11. 11
    ↵
    FendelJC, TierschC, SölderP, GaabJ, Schmidt S. Effects of open-label placebos across populations and outcomes: an updated systematic review and meta-analysis of randomized controlled trials. Sci Rep 2025; 15(1):29940. doi:10.1038/s41598-025-14895-z
  12. 12
    ↵
    LeeIS, LeeB, ParkHJ, OlaussonH, EnckP, ChaeY. A new animal model of placebo analgesia: involvement of the dopaminergic system in reward learning. Sci Rep 2015; 5:17140. doi:10.1038/srep17140
  13. 13
    ↵
    ScottDJ, StohlerCS, EgnatukCM, WangH, KoeppeRA, ZubietaJK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008; 65(2):220–231. doi:10.1001/archgenpsychiatry.2007.34
  14. 14
    ↵
    PeciñaM, ZubietaJK. Molecular mechanisms of placebo responses in humans. Mol Psychiatry 2015; 20(4):416–423. doi:10.1038/mp.2014.164
  15. 15
    ↵
    BenedettiF, AmanzioM, VighettiS, AsteggianoG. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 2006; 26(46):12014–12022. doi:10.1523/JNEUROSCI.2947-06.2006
  16. 16
    ↵
    Meeuwis SH, van Middendorp H, van Laarhoven AIM, et al. Placebo and nocebo effects for itch and itch-related immune outcomes: a systematic review of animal and human studies. Neurosci Biobehav Rev 2020; 113:325–337. doi:10.1016/j.neubiorev.2020.03.025
  17. 17
    ↵
    Pacheco-LópezG, NiemiMB, KouW, HärtingM, FandreyJ, SchedlowskiM. Neural substrates for behaviorally conditioned immunosuppression in the rat. J Neurosci 2005; 25(9):2330–2337. doi:10.1523/JNEUROSCI.4230-04.2005
  18. 18
    ↵
    HallKT, LoscalzoJ, Kaptchuk TJ. Genetics and the placebo effect: the placebome. Trends Mol Med 2015; 21(5):285–294. doi:10.1016/j.molmed.2015.02.009
  19. 19
    ↵
    Colloca L, Wang Y, Martinez PE, et al. OPRM1 rs1799971, COMT rs4680, and FAAH rs324420 genes interact with placebo procedures to induce hypoalgesia. Pain 2019; 160(8):1824–1834. doi:10.1097/j.pain.0000000000001578
  20. 20
    ↵
    CollocaL, HowickJ. Placebos without deception: outcomes, mechanisms, and ethics. Int Rev Neurobiol 2018; 138:219–240. doi:10.1016/bs.irn.2018.01.005
  21. 21
    ↵
    von WernsdorffM, LoefM, Tuschen-CaffierB, SchmidtS. Effects of open-label placebos in clinical trials: a systematic review and meta-analysis. Sci Rep 2021; 11(1):3855. doi:10.1038/s41598-021-83148-6
  22. 22
    ↵
    SchaeferM, SahinT, Berstecher B. Why do open-label placebos work? A randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis. PLoS One 2018; 13(3):e0192758. doi:10.1371/journal.pone.0192758
  23. 23
    ↵
    HróbjartssonA, GøtzschePC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344(21):1594–1602. doi:10.1056/NEJM200105243442106
  24. 24
    ↵
    KhanA, ReddingN, Brown WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res 2008; 42(10):791–796. doi:10.1016/j.jpsychires.2007.10.004
  25. 25
    ↵
    PaleseA, RossettiniG, CollocaL, TestaM. The impact of contextual factors on nursing outcomes and the role of placebo/nocebo effects: a discussion paper. Pain Rep 2019; 4(3):e716. doi:10.1097/PR9.0000000000000716
  26. 26
    ↵
    RossettiniG, PaleseA, GeriT, MirandolaM, TortellaF, TestaM. The knowledge of contextual factors as triggers of placebo and nocebo effects in patients with musculoskeletal pain: findings from a national survey. Front Psychiatry 2019; 10:478. doi:10.3389/fpsyt.2019.00478
  27. 27
    ↵
    de CraenAJ, RoosPJ, de VriesAL, KleijnenJ. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ 1996; 313(7072):1624–1626. doi:10.1136/bmj.313.7072.1624
  28. 28
    ↵
    ChaeY, LeeYS, Enck P. How placebo needles differ from placebo pills? Front Psychiatry 2018; 9:243. doi:10.3389/fpsyt.2018.00243
  29. 29
    ↵
    Espay AJ, Norris MM, Eliassen JC, et al. Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. Neurology 2015; 84(8):794–802. doi:10.1212/WNL.0000000000001282
  30. 30
    ↵
    ReynaertC, JanneP, VauseM, ZdanowiczN, Lejeune D. Clinical trials of antidepressants: the hidden face: where locus of control appears to play a key role in depression outcome. Psychopharmacology (Berl) 1995; 119(4):449–454. doi:10.1007/BF02245861
  31. 31
    ↵
    BlasiniM, PeirisN, WrightT, CollocaL. The role of patient-practitioner relationships in placebo and nocebo phenomena. Int Rev Neurobiol 2018; 139:211–231. doi:10.1016/bs.irn.2018.07.033
  32. 32
    ↵
    LafertonJAC, RiefW, Shedden-Mora M. Improving patients’ treatment expectations. JAMA 2025; 334(2):171–172. doi:10.1001/jama.2025.6261
  33. 33
    ↵
    DanialiH, FlatenMA. A qualitative systematic review of effects of provider characteristics and nonverbal behavior on pain, and placebo and nocebo effects. Front Psychiatry 2019; 10:242. doi:10.3389/fpsyt.2019.00242
  34. 34
    ↵
    KernA, KrammC, WittCM, BarthJ. The influence of personality traits on the placebo/nocebo response: a systematic review. J Psychosom Res 2020; 128:109866. doi:10.1016/j.jpsychores.2019.109866
  35. 35
    ↵
    HoringB, WeimerK, MuthER, EnckP. Prediction of placebo responses: a systematic review of the literature. Front Psychol 2014; 5:1079. doi:10.3389/fpsyg.2014.01079
  36. 36
    ↵
    Kamen C, Tejani MA, Chandwani K, et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 2014; 722:172–179. doi:10.1016/j.ejphar.2013.09.071
  37. 37
    ↵
    Rakel D, Barrett B, Zhang Z, et al. Perception of empathy in the therapeutic encounter: effects on the common cold. Patient Educ Couns 2011; 85(3):390–397. doi:10.1016/j.pec.2011.01.009
  38. 38
    ↵
    Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336(7651):999–1003. doi:10.1136/bmj.39524.439618.25
  39. 39
    ↵
    Howick J, Moscrop A, Mebius A, et al. Effects of empathic and positive communication in healthcare consultations: a systematic review and meta-analysis. J R Soc Med 2018; 111(7):240–252. doi:10.1177/0141076818769477
  40. 40
    ↵
    KellyM, SvrcekC, KingN, ScherpbierA, Dornan T. Embodying empathy: a phenomenological study of physician touch. Med Educ 2020; 54(5):400–407. doi:10.1111/medu.14040
  41. 41
    ↵
    WindoverAK, BoissyA, RiceTW, GilliganT, VelezVJ, MerlinoJ. The REDE model of healthcare communication: optimizing relationship as a therapeutic agent. J Patient Exp 2014; 1(1):8–13. doi:10.1177/237437431400100103
  42. 42
    ↵
    AltamiranoJ, KlineM, SchwartzR, FassiottoM, MaldonadoY, Weimer-ElderB. The effect of a relationship-centered communication program on patient experience and provider wellness. Patient Educ Couns 2022; 105(7):1988–1995. doi:10.1016/j.pec.2021.10.025
  43. 43
    ↵
    Graham B, Garcia NM, Burton MS, et al. High expectancy and early response produce optimal effects in sertraline treatment for post-traumatic stress disorder. Br J Psychiatry 2018; 213(6):704–708. doi:10.1192/bjp.2018.211
  44. 44
    ↵
    Mollica A, Ng E, Burke MJ, et al. Treatment expectations and clinical outcomes following repetitive transcranial magnetic stimulation for treatment-resistant depression. Brain Stimul 2024; 17(4):752–759. doi:10.1016/j.brs.2024.06.006
  45. 45
    ↵
    Rief W, Shedden-Mora MC, Laferton JAC, et al. Preoperative optimization of patient expectations improves long-term outcome in heart surgery patients. BMC Med 2017; 15(1):4. doi:10.1186/s12916-016-0767-3
  46. 46
    ↵
    EgbertLD, BattitGE, WelchCE, BartlettMK. Reduction of post-operative pain by encouragement and instruction of patients—a study of doctor-patient rapport. N Engl J Med 1964; 270: 825–827. doi:10.1056/NEJM196404162701606
  47. 47
    ↵
    Evers AWM, Colloca L, Blease C, et al. What should clinicians tell patients about placebo and nocebo effects? Practical considerations based on expert consensus. Psychother Psychosom 2021; 90(1): 49–56. doi:10.1159/000510738
View Abstract
Loading
Loading
  • Share

Subjects

Loading collections…